Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2022) 84 PS2-10-96 | DOI: 10.1530/endoabs.84.PS2-10-96

ETA2022 Poster Presentations Nodules & Cancer (10 abstracts)

Prospective, observational study on radioiodine treatment in DTC patients with intermediate RISK or micro lymph node metastases

Aleksandra Blewaska 1 , Aleksandra Ledwon 1 , Ewa Paliczka-Cieslik 1 , Aleksandra Sygula 1 , Malgorzata Haras-Gil 1 , Aleksandra Kropinska 1 , Agnieszka Czarniecka 1 & Daria Handkiewicz-Junak 2

1National Reearch Instutute of Oncology, Poland; 2National Research Institute of Oncol, National Research Institute of Oncol, Gliwice, Poland

There are much controversy adjuvant radioiodine treatment (131-I-th) in intermediate or low risk patients with lymph node micrometastases. The first results of ESTIMABL2 trial showed no radioiodine benefit in low risk DTC, however intermediate patients were not included in this study.

Aim: Observational study was to evaluate effects of 131-I-th in intermediate/low risk DTC patients.

Patients: There were 342 women (85%), the median age at diagnosis was 52. Most patients, 298 (98%), were diagnosed with papillary cancer, 117 (29%) had extrathyroid extension, 133 (33%) vascular invasion and 249 (61,6%) lymph node metastases. Median 131-I activity was 100 mCi and all patients were treated after rhTSH stimulation. Median time from first operation to 131-I-th was 5 months. Media time of follow-up after treatment 14 months.

Results: In posttherapy scintigraphy only in 9 patients there was suspicion uptake in lymph nodes. In none of these patients persistent disease was confirmed. During first follow-up 318 (79%) had excellence response and 1 structural recurrence. Thereafter 5 (1,2%) of patients recurred.

Conclusion: Our results show that in a selected group of patients with low/intermediate risk, there are excellent treatment results. The question whether 131-I-th may be omitted in this group of patients should be confirmed in a prospective randomized trial.

Volume 84

44th Annual Meeting of the European Thyroid Association (ETA) 2022

Brussels, Belgium
10 Sep 2022 - 13 Sep 2022

European Thyroid Association 

Browse other volumes

Article tools

My recent searches

No recent searches.